A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector.

•Viral vectors can provide advantages in the development of novel vaccines.•The RepliVax® platform was successfully targeted to the rabies virus G protein.•The single-cycle vaccine candidate is highly immunogenic and efficacious.•The vaccine candidate elicited highly durable, two-year long, immunity in dogs.